PaxeraHealth Corp. v. Mhanna — Suspicion of Source-Code Copying Does Not Justify an Injunction

Background

PaxeraHealth develops software that stores and displays medical images for healthcare providers. It accused former research-and-development executive Omar Mhanna of downloading source code and confidential business information shortly before leaving the company in 2023, then using that material to build competing software through HealthTom LLC.

PaxeraHealth brought copyright, trade-secret, and business-interference claims. It sought a preliminary injunction that would have broadly restricted Mhanna and HealthTom from soliciting PaxeraHealth customers and from offering medical-imaging and AI-development software. PaxeraHealth relied principally on Mhanna’s access to its files, screenshots that displayed the name of a former PaxeraHealth employee, and the speed with which HealthTom allegedly developed its product.

The Court’s Holding

Judge Myong J. Joun denied the preliminary injunction because PaxeraHealth did not show either a likelihood of success or irreparable harm. On copyright, the court accepted at this stage that PaxeraHealth plausibly owned protected software, including through Egyptian registrations recognized within the international copyright framework. But ownership was only half the inquiry. PaxeraHealth did not provide a source-code comparison, technical analysis, expert evidence, or another reliable basis for finding that HealthTom copied protectable expression.

The screenshots did not fill that gap. A user-profile tag bearing a former employee’s name did not establish how the tag was generated or rule out other explanations. The court also found that PaxeraHealth’s asserted development timeline conflicted with its own complaint: HealthTom registered its software more than two years, not three months, after Mhanna’s departure.

The trade-secret claim failed at the same preliminary stage for a related reason. PaxeraHealth adequately identified potential trade secrets—source code, marketing data, and investor materials—and alleged circumstances that could support improper acquisition. Yet it offered only conclusory assertions that the defendants actually used that information. Possession or access, without non-speculative evidence of use, was insufficient.

The court likewise found no likely tortious interference. Ordinary competition is not improper by itself, and PaxeraHealth’s theory of wrongful solicitation depended on the copyright and trade-secret theories that it had not substantiated. Finally, PaxeraHealth waited nearly three years after first suspecting the alleged taking before seeking emergency relief. That delay substantially weakened its claim of urgency, while alleged lost revenue remained compensable through damages.

Key Takeaways

• Access to source code and suspicious circumstantial evidence do not replace a technical comparison when a software owner seeks preliminary injunctive relief.
• A trade-secret claimant must show actual use or disclosure, not merely possession or an opportunity to misuse confidential files.
• Long delay can defeat irreparable-harm arguments, especially when the claimed injury is measurable lost revenue.
• Foreign copyright registrations may support ownership, but they do not relieve a plaintiff of proving actionable copying.

Why It Matters

The ruling illustrates the evidentiary discipline courts expect in emergency software disputes. A company may have strong reasons to suspect that a departing employee copied code, but broad injunctions affecting a competitor’s entire business generally require concrete proof connecting the protected material to the accused product. For software companies, that means preserving forensic records, arranging defensible code comparisons, and moving promptly once suspected misuse is discovered.

The decision does not resolve the merits of PaxeraHealth’s claims. It holds only that the present record did not justify extraordinary preliminary relief, leaving the parties to develop technical and factual proof through litigation.